# Enzymetree

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/enzymetree

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.enzymetree.cn
- Total disclosed funding: $14M
- Latest round: Series A (Jul 12, 2023)
- Investors on record: 7

## About

Founded in 2014 and based in Shanghai, China, Enzymetree is a biotech company that provides enzyme-catalyzed synthesis services. In July 2023, the firm raised approximately CNY 100 million in series A funding led by new investor Hermed Capital. Other new investors Darui Capital, Houshi Investment, Huayao Equity, Nanling Fund, and Zhuhai Hengqin Kangju Private Equity Fund Management Co., Ltd. also participated in the round. The company has cooperated with Solvay, SHV Energy and other enterprises.

The company's main products include bio-based products and pharmaceutical intermediates and enzyme products. Bio-based products include pyruvate, caffeic acid, and cinnamic acid, among others. Its products are used in food, materials, pesticides, energy, biomedicine and other industries.

## Funding rounds

- Series A, Jul 12, 2023, $14M — Hermed Capital, Nanling Fund, Zhuhai Hengqin Kangju Private Equity Fund Management Co., Ltd., Darui Capital, Houshi Investment, Huayao Equity
- Angel, Sep 18, 2017 — Longwater Investment

## Investors

- Longwater Investment (https://capitalatlas.ai/funds/longwater-investment) — Angel
- Hermed Capital (https://capitalatlas.ai/funds/hermed-capital) — Series A
- Nanling Fund — Series A
- Zhuhai Hengqin Kangju Private Equity Fund Management Co., Ltd. — Series A
- Darui Capital — Series A
- Houshi Investment — Series A
- Huayao Equity — Series A